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Abstract: Dramatic advances in the care of patients with advanced renal cell carcinoma have occurred over the last ten years, including 
insights into the molecular pathogenesis of this disease, that have now been translated into paradigm-changing therapeutic strategies. 
Elucidating the importance of signaling cascades related to angiogenesis is notable among these achievements. Pazopanib is a novel 
small molecule tyrosine kinase inhibitor that targets VEGFR-1, -2, and -3; PDGFR-α, PDGFR-β; and c-kit tyrosine kinases. This agent 
exhibits a distinct pharmacokinetic profile as well as toxicity profile compared to other agents in the class of VEGF signaling pathway 
inhibitors. This review will discuss the scientific rationale for the development of pazopanib, as well as preclinical and clinical trials that 
led to approval of pazopanib for patients with advanced renal cell carcinoma. The most recent information, including data from 2010 
national meeting of the American Society of Clinical Oncology, and the design of ongoing Phase III trials, will be discussed. Finally, an 
algorithm utilizing Level I evidence for the treatment of patients with this disease will be proposed.
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Introduction
Renal cell carcinoma
Renal  cell  carcinoma  (RCC)  was  the  ninth  most 
  common cancer diagnosed in the United States dur-
ing  2009,  with  nearly  58,000  new  diagnoses  and 
almost 13,000 deaths.1 Sporadic RCC has numerous 
  histologic subtypes that occur with varying incidences, 
including clear cell carcinoma (75%), papillary (12%, 
chromophobe  (4%),  oncocytoma  (4%),  collecting 
duct (,1%) and unclassified (3%–5%).2,3 The his-
tologic classifications of clear cell and predominant 
clear cell carcinoma are the most commonly identified 
subtypes and thus the best studied to date. The main-
stay of treatment is radical nephrectomy for localized 
disease, and until recently, the treatment options for 
patients with either unresectable or metastatic renal 
cell carcinoma were limited.
Prior to the advent of targeted therapy, the prog-
nosis of patients with metastatic renal cell carcinoma 
was very poor, with a median survival of one year 
and a five-year survival of 0%–20%.4 Historically, 
treatment of metastatic renal cell carcinoma involved 
immunotherapeutic agents such as interferon (IFN-α) 
or interleukin-2 (IL-2).5 IFN-α has been shown to pro-
vide a benefit in terms of overall survival compared 
to inactive therapy but with an average response rate 
between 10%–15% and few durable responses. High-
dose IL-2 (infusion therapy requiring hospitalization) 
has a higher overall and complete response (CR) rate 
compared  with  low-dose  cytokines  (subcutaneous, 
outpatient), with the real benefit realized in the small 
percentage (5% to 7%) of patients who experience a 
durable CR.6 The patient most likely to obtain a dura-
ble CR with high-dose IL-2 includes the young, previ-
ously untreated patient with clear-cell   histology RCC, 
ECOG  performance  status  0,  and  limited    volume 
metastatic disease to lung. The   morbidity and lack of 
applicability of high dose IL-2 to the broad RCC pop-
ulation has dampened enthusiasm for this approach, 
although it remains a valid treatment option in a very 
limited subset of patients.
The von Hippel Lindau gene in RCC
Of critical importance in the pathogenesis of clear cell 
RCC is the von Hippel-Lindau (VHL) tumor suppres-
sor gene,7 the understanding of which has revolution-
ized RCC treatment. The VHL gene encodes the VHL 
protein, which is composed of an E3 ubiquitin ligase 
involved in the degradation of the transcription factor 
hypoxia-inducible factor (HIF). In RCC, one allele of 
the VHL gene is inactivated through a deletion event 
that can be observed in .90% of sporadic clear cell 
RCC.8 The remaining VHL allele is also commonly 
affected,  with  inactivation  in  up  to  50%  of  clear 
cell RCC through gene mutation and an additional 
5%–10%  via  altered  methylation  patterns.9,10  This 
biallelic gene inactivation leads to intracellular accu-
mulation of the HIF transcription factor. Dimerization 
of the HIF isoforms, HIF-α and HIF-β, leads to upreg-
ulation of hypoxia-inducible genes such as VEGF, 
platelet-derived growth factor (PDGF), transforming 
growth factor (TGF) and others.5 This overabundance 
of HIF thus results in a cascade of overexpression of 
multiple growth factors that are normally reserved for 
cellular responses to hypoxia.
The veGF signaling pathway and vHL
Extensive work has further clarified the VEGF axis 
as  it  relates  to  tumorogenesis  in  clear  cell  RCC.11 
Increased levels of circulating angiogenesis factors 
like  basic  fibroblast  growth  factor  (bFGF), VEGF, 
and angiogenin can be found in the serum of renal 
cancer  patients,  consistent  with  the  hypervascular 
nature of these tumors.4,12–14 The VEGF ligand family 
includes four protein isoforms, VEGF-A, -B, -C, -D, 
that differentially interact with cell surface receptors 
to initiate a cascade of downstream signaling events.15 
The number of receptors able to bind VEGF isoforms 
as well as the complexity of the interactions between 
various signaling cascades in angiogenic pathways 
has both complicated drug development in this field 
and simultaneously provided new targets for thera-
peutic agents.
VEGF  receptors  are  members  of  a  family  of 
  transmembrane tyrosine kinase receptors that medi-
ate  signal  transduction  from  extracellular  signal-
ing  ligands,  like  VEGF,  to  intracellular  signaling 
cascades. Members of this receptor family include 
VEGFR-1  (Flt-1),  VEGFR-2  (KDR/Flk-1),  and 
VEGFR-3  (Flt-4).  Similar  to  Kit  and  platelet-
derived  growth  factor  (PDGF)  receptors,  VEGF 
receptors are activated upon ligand-mediated recep-
tor  dimerization.16  VEGF-A  binds  to  VEGFR-1 
and -2, while VEGF-C and -D bind to VEGFR-2 
and -3. Each receptor   subtype interacts with differ-
ent   signaling molecules at the plasma membrane to Pazopanib in advanced renal cell carcinoma
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activate different cellular processes. For example, 
activation of VEGFR-2 by VEGF-A leads to activa-
tion of Raf and the mitogen-activated protein kinase 
(MAPK) pathway via phospholipase C-γ (PLC-γ) in 
the endothelial cell. Activation of these intracellu-
lar signaling cascades promote tumor angiogenesis 
via  multiple  mechanisms  that  include  endothelial 
cell survival, proliferation, and migration.16 These 
molecular  findings  are  consistent  with  historical 
descriptions  of  increased  vascularity  of  renal  cell 
tumors and correlate with elevated VEGF protein in 
tumor and serum samples.
Therapy targeting the veGF ligand
The  first  VEGF  targeted  therapy  to  receive  FDA 
approval in solid tumors was bevacizumab. This well-
studied  agent  is  a  monoclonal  antibody  that  binds 
VEGF-A and has been shown to improve overall sur-
vival in multiple solid tumors when combined with 
chemotherapy. It has also demonstrated single-agent 
activity in a randomized Phase II trial in renal cell 
carcinoma.17 More recently, the FDA has approved 
bevacizumab in combination with IFN-α for the treat-
ment of metastatic renal cell carcinoma on the basis 
of improvements in progression free survival (PFS) 
compared to IFN-α alone in the AVOREN (median 
PFS 10.2 versus 5.4 months, HR = 0.63, P , 0.0001) 
and CALBG 90206 (median PFS 8.5 months versus 
5.2 months, HR = 0.71 P , 0.0001) trials.18,19 While nei-
ther trial met the primary endpoint of overall survival, 
both showed nonsignificant trends toward increased 
median  survival  in  the  bevacizumab-containing 
arms. The dramatic improvements in PFS resulted in 
FDA approval in this setting. Of note, with multiple 
therapies now approved and widely available, many 
patients received second and even third line therapies 
(including additional VEGF signaling pathway tar-
geted agents). These findings have contributed to the 
significant debate in the field regarding the impact of 
post protocol therapies on overall survival data.
Therapy targeting the veGF receptor
The  VEGF  Receptor  Tyrosine  Kinase  Inhibitor 
(VEGFR  TKI)  family  of  drugs  continues  to  grow 
and  includes  agents  such  as  Sorafenib,  Sunitinib, 
  Axitinib and Pazopanib. This class is broadly defined 
as small molecule inhibitors of the VEGF signaling 
cascade that exert their mechanism via blockade of 
one or more VEGFR tyrosine kinases. These four 
drugs all exhibit the ability to inhibit VEGF receptor 
1, 2 and 3, PDGFR and c-kit. They differ in other off 
target effects including Raf kinase (sorafenib), RET 
(sorafenib and sunitinib), and FLT3 (sunitinib). They 
further differ in pharmacokinetic properties such as 
kinase IC50, terminal half life, and Cmax.20–23 As clini-
cal trials with these varied agents reach maturity, we 
are beginning to discriminate differences in both effi-
cacy and toxicity profiles among these agents. The 
first of the VEGFR TKIs to receive FDA approval 
was  sorafenib,  based  on  the  randomized,  placebo 
controlled Phase III trial by Escudier et al showing an 
improved PFS of 5.5 months in the sorafenib group 
versus 2.8 months in the placebo group in a cytokine-
refractory population (hazard ratio, 0.44; 95% confi-
dence interval [CI], 0.35 to 0.55; P , 0.01).24 Sunitinib 
was later approved for treatment of mRCC based on 
the  randomized  Phase  III  trial  showing  improved 
PFS  of  11  months  for  sunitinib  compared  with 
5 months for IFN-α in a treatment-naïve population 
(P , 0.001).25,26 Recent Phase II and Phase III trials 
with other agents in the VEGFR TKI family of drugs 
have recently been reported for treatment of mRCC. 
This article will review the clinical trials conducted 
with the VEGFR TKI pazopanib to date (as summa-
rized in Table 1) and discuss the evidence-based role 
of pazopanib for the treatment of advanced renal cell 
carcinoma with predominant clear cell histology.
Mechanism of Action, 
pharmacokinetic, and Metabolism 
Profile of Pazopanib
Pazopanib (GW786034, Votrient®; GlaxoSmithKline) 
is a potent and selective, orally available, small mol-
ecule inhibitor of VEGFR-1, -2, and -3; PDGFR-α, 
PDGFR-β; and c-kit tyrosine kinases.27,28 The agent 
selectively inhibits proliferation of endothelial cells 
stimulated with VEGF but not with basic fibroblast 
growth  factor.  In  preclinical  angiogenesis  models, 
pazopanib  inhibited VEGF-dependent  angiogenesis 
in a dose-dependent manner, and in xenograft tumor 
models twice-daily administration of pazopanib sig-
nificantly inhibited tumor growth in mice implanted 
with  various  human  tumor  cells.29  Pharmacoki-
netic and pharmacodynamic studies showed that a 
pazopanib  concentration  of  $40  µmol/L  inhibited 
VEGFR-2 in mice. These data differed from the IC50 of Lang and Harrison
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0.02 µmol/L based on VEGF-stimulated   proliferation 
in cell culture models and was attributed to in vivo 
protein binding of pazopanib.29 A target steady-state 
concentration of $40 µmol/L was thus selected for 
the Phase I trial and achieved in patients receiving 
either 800 mg daily or 300 mg BID.23
Pazopanib  is  absorbed  orally  with  median  time 
to peak plasma concentrations of 2 to 4 hours and a 
mean half-life of 30.9 hours after administration of 
an 800 mg dose.23 Daily dosing at 800 mg resulted 
a  in  mean  AUC  of  1,037  hr  µg/mL  and  Cmax  of 
58.1 µg/mL with no consistent increase in AUC or 
Cmax at pazopanib doses above 800 mg.23 Adminis-
tration of a single pazopanib 400 mg crushed tablet 
increased Cmax approximately 2 fold and decreased tmax 
by approximately 2 hours compared to administration 
of the whole tablet, indicating increased bioavailabil-
ity and rate of oral absorption after administration 
of a crushed tablet. Systemic exposure to pazopanib 
was increased with a high-fat or low-fat meal result-
ing in an approximately 2-fold increase in AUC and 
Cmax leading to the recommendation that pazopanib 
be administered at least 1 hour before or 2 hours after 
a meal.30 Further pharmacokinetic data from patients 
with normal hepatic function (n = 12) and moderate 
(n = 7) hepatic impairment indicate that pazopanib 
clearance was decreased by 50% in those with mod-
erate  hepatic  impairment.31 The  pazopanib  dose  in 
patients with moderate hepatic impairment is recom-
mended at 200 mg once daily.30
In  vitro  studies  demonstrated  that  pazopanib  is 
metabolized by CYP3A4 with a minor contribution 
from CYP1A2 and CYP2C8. Co-administration of 
oral pazopanib with CYP3A4 inhibitors has resulted 
in  increased  plasma  pazopanib  concentrations.  For 
example, administration of 1,500 mg lapatinib, a sub-
strate and weak inhibitor of CYP3A4, with 800 mg 
pazopanib resulted in an approximately 50% to 60% 
increase in mean pazopanib AUC(0–24) and Cmax com-
pared to administration of 800 mg pazopanib alone.32 
Clinical  pharmacology  studies  using  pazopanib 
800 mg once daily have demonstrated that pazopanib 
does not have a clinically relevant effect on the phar-
macokinetics of caffeine (CYP1A2 probe substrate),30 
warfarin  (CYP2C9  probe  substrate),  or  omepra-
zole  (CYP2C19  probe  substrate).  Co-administra-
tion of pazopanib 800 mg once daily and paclitaxel 
80  mg/m2  (CYP3A4  and  CYP2C8  substrate)  once 
weekly resulted in a mean increase of 26% and 31% 
in paclitaxel AUC and Cmax, respectively.33
Clinical Safety and Efficacy
Pazopanib Phase I experience
A  company-sponsored  phase  I  study  of  orally 
  administered  pazopanib  enrolled  63  patients  with 
a  variety  of  solid  tumor  types  (dose  escalation, 
n  =  43;  dose  expansion,  n  =  20).23  Doses  admin-
istered ranged from 50 mg three times per week to 
2000 mg once daily to 400 mg twice daily. Tumor 
shrinkage was observed in two of twelve renal cell 
carcinoma patients, with confirmed partial responses. 
Of the remaining ten renal cell carcinoma patients, 
stable disease was observed in four patients and pro-
gressive  disease  in  four  patients.  Two  other  renal 
Table 1. Clinical trials of pazopanib in patients with renal cell carcinoma.
study Dose setting no. of pts 
with mRcc
MsKcc risk 
category37,38 
(F/I/p/U§)
prior  
nephrectomy
clear cell 
Phase I23 A.   50 mg and 100 mg  
three times weekly
B.   50 to 2,000 mg 
once daily
C.   300 mg and 400 mg 
twice daily.
Dose 
escalation
12/63 NR NR NR
Phase II34 800 mg once daily 
versus placebo
First-line, 
cytokine-naïve
225 43/41/2/14% 91% Yes†
Phase III36 800 mg once daily 
versus placebo
First-line, pre- or 
post- cytokine
290* 39/55/3/3%* 89%* Yes†
notes: *Pazopanib arm only; †Clear cell or predominantly clear cell histology required.
Abbreviations: §F/I/P/U, favorable, intermediate, poor, or unknown risk status; NR, not reported.Pazopanib in advanced renal cell carcinoma
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cell    carcinoma  patients  were  withdrawn  from  the 
study due to toxicity before the first disease assess-
ment. Tumor shrinkage was also seen in patients with 
Hurthel cell and neuroendocrine tumors, as well as 
chondrosarcoma. In all, 17 patients, including those 
with RCC, Hurthel cell, carcinoid, GIST, neuroendo-
crine, sarcoma, melanoma, and lung cancer tumors, 
remained on study for 6 months or longer. Pazopanib 
was generally well tolerated up to 2,000 mg. How-
ever, the pharmacokinetic analysis demonstrated that 
a plateau in steady state exposure was observed from 
800 mg to 2000 mg doses. On the basis of this find-
ing, a traditional maximum tolerated dose was not 
established and the recommended phase II dose was 
set at 800 mg, administered one hour before or two 
hours after a meal.23
The most common adverse events (AEs) seen in 
this phase I trial regardless of causality were all grade 
1 or 2.23 Forty eight (76%) patients experienced drug-
related AEs with the most frequently reported of all 
grades including hypertension (33%), diarrhea (33%), 
hair depigmentation (32%), and nausea (32%). One of 
three patients treated with 2000 mg daily of pazopanib 
developed dose-limiting toxicity of grade 3 fatigue. 
Hair depigmentation (indicative of c-kit and, poten-
tially, VEGFR modulation) was seen in 12 patients, 
all of whom were treated at doses $ 800 mg. One of 
three patients dosed at 2000 mg once daily experi-
enced grade 3 fatigue that resolved upon dose reduc-
tion to 800 mg. As seen with many VEGF signaling 
pathway inhibitors, grade 1–3 hypertension that could 
be controlled with antihypertensive medication was 
observed in the phase I study. In addition, there were 
single events of gastrointestinal bleeding, pulmonary 
thrombosis, and deep vein thrombosis. Pazopanib did 
not affect QTc in this phase I trial, nor was hand foot 
syndrome observed.23,24
Pazopanib Phase II results in metastatic 
renal cell carcinoma
Upon designation of the recommended phase II dose of 
pazopanib, a randomized, discontinuation phase 2 trial 
was designed for patients with metastatic or locally 
recurrent RCC.34 Study patients were required to have 
predominantly clear cell histology with measurable 
disease who had received either no systemic therapy 
or 1 prior systemic therapy, that may have included 
bevacizumab. Pazopanib was administered at 800 mg 
PO daily until progression of disease. The primary 
end point was progressive disease rate at 16 weeks 
post randomization. Two hundred twenty-five patients 
with metastatic RCC were treated (69% were previ-
ously untreated and 84% had favorable or intermedi-
ate risk). Interestingly, after a planned interim analysis 
showing indication of activity, the study was changed 
to an open-label trial design. At that time, the primary 
endpoint was changed to overall response rate accord-
ing  to  RECIST  guidelines. Accrual  was  completed 
by this interim analysis and the amendment allowed 
patients with stable disease who had been random-
ized to placebo to restart the study drug (n = 28). The 
PFS  attributable  to  pazopanib  was  estimated  using 
  Kalbfleish-Prentice  estimation  to  account  for  these 
patients. The independently reviewed overall response 
rate was 34.7% (95% CI, 28% to 41%), and the median 
PFS was 51.7 weeks. The PFS in the randomized com-
parison (n = 55) was 11.9 months for pazopanib versus 
6.2 months for placebo (P = 0.0128).
Further analysis of this study was recently reported 
at the 2010 American Society of Clinical Oncology 
meeting. Suttle et al performed a retrospective analy-
sis of the pharmacokinetics of pazopanib as related to 
patient outcome.35 Of the 225 patients enrolled on the 
trial, Cmin data was available for 205 patients at four 
weeks and 185 patients at 12 weeks. When separated 
into quartiles and stratified by PFS, it was observed 
that patients with a week 4 Cmin . 20.6 µg/mL had 
a median PFS of 49.4 weeks versus 20.3 weeks for 
patients unable to achieve this plasma level of drug. 
In addition, response rate was improved in this group 
(45%  versus  18%),  as  was  mean  percent  tumor 
shrinkage (37.8% vs. 8.8%). Importantly, nearly 70% 
of patients assessed at this time point (143/205) were 
able to reach or exceed this drug level. No data related 
to toxicity stratified by plasma level was available. 
While still a retrospective analysis, these data support 
both the initial dosage chosen for this drug as well as 
a potential role for maintaining dose intensity during 
treatment whenever possible.
Pazopanib Phase III results  
in metastatic renal cell carcinoma
The results of a single phase III trial with pazopanib 
in  metastatic  renal  cell  carcinoma  were  recently Lang and Harrison
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published  by  Sternberg  et  al.36  This  trial  was  a 
  randomized,  double  blind,  placebo  controlled  trial 
in  patients  with  clear  cell,  or  predominantly  clear 
cell, histology who either received no prior therapy 
or who had progressed on one prior cytokine-based 
systemic therapy. Patients were randomized in a 2:1 
fashion to receive pazopanib at 800 mg once daily 
or placebo. Randomization was stratified according 
to performance status, prior nephrectomy, and treat-
ment history. Patients who progressed on the placebo 
arm were allowed to enroll on an open label study of 
pazopanib, with seventy patients (48%) choosing this 
option. The primary endpoint of this trial was pro-
gression free survival with secondary endpoints of 
overall survival, confirmed objective response rate, 
duration of response, and safety.
Between April 2006 and April 2007, 435 patients 
were enrolled from 80 centers worldwide, with 290 
randomized to pazopanib and 145 to placebo. The 
experimental and control arms were well balanced 
with regards to MSKCC risk category (94% vs. 92% 
with  favorable/intermediate  group,    respectively) 
and prior nephrectomy (89% vs. 88%,   respectively). 
The study was originally designed to include only 
cytokine-pretreated patients, but was rapidly amended 
to include treatment-naïve patients as well. Therefore, 
of the patients enrolled, 233 (54%) were treatment-
naïve  and  202  (46%)  had  been  previously  treated 
with IFN-α or IL-2. The experimental and control 
arms were well balanced in this regard, with the per-
centage of treatment naïve patients at 53% vs. 54%, 
respectively.
Pazopanib  was  found  to  significantly  improve 
PFS compared to placebo (median 9.2 months vs. 
4.2 months; HR, 0.46; 95% CI, 0.34 to 0.62; P , 0.0001) 
in the overall study population. The improvement in 
PFS  was  more  pronounced  in  the  treatment  naïve 
subpopulation  (median  11.1  vs.  2.8  months;  HR, 
0.40; 95% CI, 0.27 to 0.60; P , 0.0001), though the 
pretreated  subpopulation  also  showed  a  significant 
improvement (median 7.4 vs. 4.2 months, HR, 0.54; 
95% CI, 0.35 to 0.84; P , 0.001) as well. The objec-
tive response rate in this study was 30% (95% CI, 
25.1 to 35.6), with a median duration of response of 
58.7 weeks. At the time of reporting, the percentage 
of patients on study greater than 12 months reached 
32% in the pazopanib arm and 15% in the placebo 
arm.  Interim  overall  survival  results  did  not  meet 
  significance and final results will be reported when 
data mature. Importantly, predefined subgroup analy-
ses of PFS supported the pazopanib arm in all catego-
ries (MSKCC risk category, treatment history, gender, 
age, performance status).
Further trials with pazopanib include: 1) the exten-
sion trial of patients enrolled to the placebo arm in 
the Phase III trial (discussed above); 2) an ongoing 
phase  III  open-label  trial,  COMPARZ  (Pazopanib 
Versus Sunitinib in the Treatment of Subjects With 
Locally Advanced and/or Metastatic Renal Cell Car-
cinoma); and the PISCES (Patient Preference Study 
of Pazopanib Versus Sunitinib in Advanced or Meta-
static Kidney Cancer) trial. The COMPARZ trial is 
designed to test pazopanib versus sunitinib (Sutent
®, 
Pfizer) in locally advanced and/or metastatic RCC 
patients who have had no prior treatment. Approxi-
mately 876 patients with treatment naïve metastatic 
clear cell RCC will be included. The PISCES trial 
will address patient preferences between pazopanib 
and  sunitinib.  This  trial  is  a  randomized,  double-
blind, crossover study of pazopanib versus sunitinib 
in patients with metastatic RCC who have received no 
prior systemic therapy. Approximately 160 patients 
are planned.37
Adverse events with pazopanib
Pazopanib exhibits a similar toxicity profile to other 
agents in the VEGFR TKI class of agents as summa-
rized in Table 2. Although comparisons across trials 
do not allow definitive conclusions, there appears to 
be a lower incidence of hand foot syndrome, diarrhea, 
asthenia and myelosuppression in the Phase III trial 
with pazopanib compared to the Phase III trials of 
sunitinib and sorafenib. There was a 40% incidence 
of hypertension in the phase III trial with pazopanib 
which appears to be somewhat higher compared to 
other VEGFR TKIs. Of note, the incidence of Grade 3 
hypertension was less than 1% and 4% of patients on 
the Phase II and Phase III trials, respectively. Arte-
rial thrombotic events occurred in 3% of pazopanib-
treated  patients,  of  which  2%  were  myocardial 
infarction/ischemia and 1% due to cerebrovascular 
accident/TIA. The incidence of hemorrhagic events 
(all grades) in the pazopanib arm was 13% compared 
with 5% in the placebo arm. Laboratory abnormali-
ties observed included predominantly grade 1/2 elec-
trolyte abnormalities, including hypo-phosphatemia, Pazopanib in advanced renal cell carcinoma
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Table 2. Adverse events reported in Phase III trials with veGFR TKIs.
Adverse events pazopanib (%)36 sunitinib (%)25 sorafenib (%)24
All G3–4 All G3–4 All G3–4
AST elevation 53 9 52 2 – –
ALT elevation 53 12 46 2 – –
Hyperglycemia 41 1 – –
Hypertension 40 4 24 8 17 4
Neutropenia 34 2 72 11 – –
Thrombocytopenia 32 1 65 8 – –
Bleeding 13 NR 12 1 15 3
Rash – – 19 2 40 1
Fatigue/asthenia 19 3 51 7 37 5
Diarrhea 11 4 53 5 43 2
Stomatitis ,0 ,1 25 1 NR 1
Hand-foot syndrome ,0 ,1 20 5 30 6
Hypothyroidism – – 6 1 – –
Heart failure – – 10 2 3 3
Renal impairment – – 66 1 – –
-calcemia, -natremia, and -magnesemia. In combina-
tion with clinical findings of prolonged QT intervals 
and torsades de pointes, this led to the recommenda-
tion that electrocardiograms and electrolytes be mon-
itored in patients considered at risk.30
Death resulting from AEs was reported in 4% of 
patients in the pazopanib arm and 3% of patients in 
the placebo arm. Four patients (1%) in the pazopanib 
arm had fatal AEs that were assessed by the investiga-
tor as attributable to study treatment: ischemic stroke, 
abnormal  hepatic  function  and  rectal  hemorrhage, 
peritonitis/bowel perforation, and abnormal hepatic 
function (one patient each). Importantly, of the two 
patients who died of peritonitis/bowel perforation in 
the phase II and phase III trials, one had RCC metas-
tasis present at the site of perforation and the other 
had a history of diverticulitis.
A  major  difference  with  pazopanib  and  other 
VEGFR TKIs includes an apparent higher probabil-
ity of severe hepatotoxicity and hyperbilirubinemia 
with pazopanib. Elevations in the liver enzyme ALT 
occurred in 65% of patients, of which 12% experi-
enced Grade 3–4 toxicity. ALT elevation recovered 
to  #grade  1  after  dose  modification,  interruption 
or  cessation  of  drug  in  87%  of  patients  while  the 
remaining  13%  did  not  have  adequate  follow  up 
data  for  reporting.  One  patient  died  of  abnormal 
hepatic function that was attributed to study drug was 
later found to have extensive hepatic infiltration of 
tumor. These findings led to a black box warning for 
pazopanib   stating “Increases in serum transaminase 
levels and bilirubin were observed. Severe and fatal 
hepatotoxicity has occurred. Measure liver chemis-
tries before the initiation of treatment and regularly 
during treatment”. A genetic analysis performed by 
Xu et al attempted to identify genetic markers that 
may   predict risk of ALT and/or bilirubin elevation in 
patients treated with pazopanib.38 Serum samples from 
225 patients from the Phase II trial and 290 patients 
from the Phase III trial were analyzed for numerous 
genetic polymorphisms. Interestingly, the UGT1A1 
TA repeat polymorphism was strongly associated with 
maximum on-treatment bilirubin concentration and 
bilirubin increase from baseline. None of the other 
markers tested was related to elevation of ALT. While 
screening for the UGT1A1 TA repeat polymorphism 
was not recommended, it is important to consider that 
isolated elevations of total bilirubin may not indicate 
pazopanib-induced hepatotoxicity.
patient preference
Overall  patient  preference  amongst  the  evidence-
based first-line treatments for favorable or intermedi-
ate risk metastatic renal cell carcinoma is unknown. 
These questions have been examined in retrospective 
studies, but may be subject to bias. Discussion of 
both side effects and the convenience of oral therapy, 
among other factors, will be critical in the decision-
making process for patients with mRCC. Although 
the lack of head-to-head comparison studies limits Lang and Harrison
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  definitive    conclusions,  we  believe  pazopanib  may 
exhibit  several  key  differences  versus  previously 
approved VEGFR TKIs. Reviewing the toxicity pro-
files of VEGFR TKIs in renal cell carcinoma would 
suggest  that  the  lower  incidence  of  fatigue,  diar-
rhea and hand-foot syndrome might favor pazopanib 
(Table 2). However, patients with poorly controlled/
difficult to treat hypertension or baseline liver dys-
function  may  well  have  greater  difficulty  with 
pazopanib. These questions regarding patient prefer-
ences and differential toxicity profiles will hopefully 
be  answered  more  definitively  in  the  prospective 
PISCES study discussed above.
pazopanib: place in Therapy
Treatment naïve patients
With the dramatic advances in treatment of mRCC, a 
question that would have been unheard of ten years 
ago now comes to the forefront: What is the best first 
line systemic therapy for mRCC? We support an evi-
dence-based approach to upfront therapy based on the 
inclusion criteria in phase III trials and other patient 
characteristics.  Important  factors  include  MSKCC 
risk group,39,40 number and type of prior therapies, 
histologic  subtype,  and  patient-specific  factors. 
The strongest evidence for pazopanib is in the first 
line setting for patients with favorable/intermediate 
risk, predominantly clear cell renal carcinoma (see 
Figure  1).  Other  appropriate  agents  for  treatment-
  naïve patients falling into an intermediate or favor-
able  risk  group  include  sunitinib,  or  bevacizumab 
plus    interferon-α.2,5,39,41  For  poor  risk  or  non  clear 
cell histology patients, there is Level 1 evidence for a 
survival advantage of temsirolimus, an intravenously 
administered  inhibitor  of  the  mammalian  target  of 
rapamycin (mTOR) pathway, when compared with 
interferon-α alone in the first line setting.42 Patients’ 
co-morbidities which could be exacerbated by agent-
specific toxicities should be considered before ini-
tiating treatment. Other factors that may play a role 
include convenience of oral agents as well as prescrip-
tion drug coverage status (ie, out-of-pocket cost).
Treatment options in the second line setting, after 
progression on a first line VEGF signaling pathway 
MSKCC risk status39,40
1. Time from initial RCC diagnosis to start of therapy less than 1 year. 
2. High lactate dehydrogenase; >1.5x ULN 
3. Low serum hemoglobin 
4. High corrected serum calcium; >10 
5. Number of metastatic sites ≥2
Favorable:  0  Risk factors 
Intermediate: 1 or 2 Risk factors 
Poor:  ≥3 Risk factors 
Advanced renal 
carcinoma:  
Favorable or intermediate 
MSKCC risk, clear cell 
component* 
Pazopanib 
Sunitinib 
P
R
O
G
R
E
S
S
I
O
N
Everolimus 
Clinical trial 
High dose IL2 
Bevacizumab/
interferon
(selected group) 
First line Second line
Dosing of agents
1. Pazopanib 800 mg PO Daily for 4 weeks36
2. Sunitinib 50 mg PO Daily for 4 weeks on 
followed by 2 weeks off25
3. Bevacizumab 10 mg/kg D1 and D5; 
Interferon 9 MU SQ 3 times/week18,19
4. High Dose IL2 600,000 or 720,000 IU/kg IV 
q8 hours for up to 14 consecutive doses over 
5 days6
5. Everolimus 10 mg PO Daily for 4 weeks41
Figure 1. evidence-based treatment algorithm for treatment-naïve metastatic renal cell carcinoma (category 1).
note: *Temsirolimus is FDA approved for the first line treatment of poor risk or non clear cell histology metastatic renal cell carcinoma (category 1).42Pazopanib in advanced renal cell carcinoma
Clinical Medicine Insights: Oncology 2010:4  103
agent, are even less clear. Inhibitors of the mammalian 
target  of  rapamycin  (mTOR)  pathway,  including 
everolimus,  have  been  reported  to  show  efficacy 
in the second line setting.41 The strongest evidence 
  supports everolimus after progression on TKIs. The 
role of VEGFR TKI therapies as second line treat-
ment options are currently being evaluated in clinical 
trials, with the only published data in smaller phase II 
trials testing sorafenib either before or after treatment 
with sunitinib. However, the critical questions are: 
By  what  mechanisms  does  angiogenesis  inhibition 
fail and what rationale would support their continued 
use? Reports of increasing serum VEGF levels during 
treatment with VEGFR TKIs would support continued 
use of these agents with alternative dosing strategies.43 
This hypothesis is supported by a Phase II trial with 
escalated dose sorafenib showing a responses in 42% 
of patients who had progressed on standard dose.44 
Other Phase II trials have shown response rates with 
sunitinib in bevacizumab refractory disease12 and axi-
tinib in sorafenib refractory disease.22 Whether these 
results are related to more potent VEGF inhibition or 
inhibition of additional targets is unclear. However, 
these results do suggest that VEGF signaling path-
way inhibitors could play an important role as second 
line therapies and beyond. A phase III trial comparing 
sorafenib and sunitinib sequencing (NCT00732914) 
is designed to address a related VEGFR TKI sequenc-
ing question. Whether the results of this trial will be 
applicable to other VEGFR TKIs such as pazopanib 
and axitinib is unclear.
Cytokine-refractory patients
With  the  approval  of  six  targeted  therapy  regimens 
for advanced renal cell carcinoma, the population of 
cytokine-refractory patients is dramatically shrinking. 
Therefore, the question of how to use these novel agents 
in cytokine-refractory disease is currently less pressing. 
However, randomized controlled studies of pazopanib36 
and sorafenib24 provide category 1 (ie, Phase III RCT 
data) evidence supporting their use in this population 
(See Figure 2). As the use of VEGFR signaling path-
way inhibitors for first line treatment is now standard of 
care, we expect to see fewer and fewer cytokine-refrac-
tory patients in clinical practice in the upcoming years.
conclusion
Pazopanib is a novel VEGFR TKI that has now dem-
onstrated efficacy in a randomized Phase III trial in 
metastatic renal cell carcinoma in both the front line 
and cytokine-refractory settings. The unique toxicity 
profile of this agent, as well as the convenience of an 
oral therapy, makes it an attractive option in treatment 
of  mRCC.  Further  trials  defining  the  comparative 
efficacy, toxicity, and patient preference of pazopanib 
versus other VEGFR TKIs are currently underway. 
Further research to test the efficacy of this agent in 
the setting of patients who have failed prior VEGF 
blockade (bevacizumab, sunitinib, etc.) is needed.
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